PA8521901A1 - Derivados de 2h-tetrazol-5-il- amida - Google Patents

Derivados de 2h-tetrazol-5-il- amida

Info

Publication number
PA8521901A1
PA8521901A1 PA20018521901A PA8521901A PA8521901A1 PA 8521901 A1 PA8521901 A1 PA 8521901A1 PA 20018521901 A PA20018521901 A PA 20018521901A PA 8521901 A PA8521901 A PA 8521901A PA 8521901 A1 PA8521901 A1 PA 8521901A1
Authority
PA
Panama
Prior art keywords
rent
hydrogen
amida
tetrazol
derivatives
Prior art date
Application number
PA20018521901A
Other languages
English (en)
Spanish (es)
Inventor
Synese Jolidon
Vincent Mutel
Eric Vieira
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8521901A1 publication Critical patent/PA8521901A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • C07D257/06Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PA20018521901A 2000-07-13 2001-07-10 Derivados de 2h-tetrazol-5-il- amida PA8521901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115170 2000-07-13

Publications (1)

Publication Number Publication Date
PA8521901A1 true PA8521901A1 (es) 2002-04-25

Family

ID=8169240

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018521901A PA8521901A1 (es) 2000-07-13 2001-07-10 Derivados de 2h-tetrazol-5-il- amida

Country Status (19)

Country Link
US (1) US6399641B1 (enExample)
EP (1) EP1303499B1 (enExample)
JP (1) JP3971298B2 (enExample)
KR (1) KR100504292B1 (enExample)
CN (1) CN1214017C (enExample)
AR (1) AR029706A1 (enExample)
AT (1) ATE332895T1 (enExample)
AU (2) AU2001278472B2 (enExample)
BR (1) BR0112465A (enExample)
CA (1) CA2415673A1 (enExample)
DE (1) DE60121447T2 (enExample)
DK (1) DK1303499T3 (enExample)
ES (1) ES2267797T3 (enExample)
MX (1) MXPA03000221A (enExample)
PA (1) PA8521901A1 (enExample)
PE (1) PE20020409A1 (enExample)
PT (1) PT1303499E (enExample)
WO (1) WO2002006254A1 (enExample)
ZA (1) ZA200210157B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ619746A (en) 2003-08-06 2014-05-30 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
CN1934094A (zh) * 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
MY158077A (en) 2005-02-04 2016-08-30 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8148536B2 (en) 2006-04-21 2012-04-03 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1343827A (en) * 1971-06-15 1974-01-16 Science Union & Cie Acylaminotetrazoles and process for preparing them
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
GB9626151D0 (en) * 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds
AU763245B2 (en) * 1997-12-10 2003-07-17 Nps Pharmaceuticals, Inc. Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives

Also Published As

Publication number Publication date
DK1303499T3 (da) 2006-10-30
ATE332895T1 (de) 2006-08-15
AU2001278472B2 (en) 2006-08-03
WO2002006254A1 (en) 2002-01-24
KR20030016390A (ko) 2003-02-26
MXPA03000221A (es) 2003-06-06
AR029706A1 (es) 2003-07-10
JP3971298B2 (ja) 2007-09-05
CA2415673A1 (en) 2002-01-24
AU7847201A (en) 2002-01-30
PT1303499E (pt) 2006-11-30
JP2004504308A (ja) 2004-02-12
CN1441791A (zh) 2003-09-10
BR0112465A (pt) 2003-07-22
CN1214017C (zh) 2005-08-10
EP1303499B1 (en) 2006-07-12
KR100504292B1 (ko) 2005-07-28
PE20020409A1 (es) 2002-05-21
US20020022648A1 (en) 2002-02-21
US6399641B1 (en) 2002-06-04
ZA200210157B (en) 2004-03-15
DE60121447D1 (de) 2006-08-24
EP1303499A1 (en) 2003-04-23
DE60121447T2 (de) 2007-02-01
ES2267797T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
PA8521901A1 (es) Derivados de 2h-tetrazol-5-il- amida
ES2165357T3 (es) Derivados de metileno-oxiindol y procedimiento de elaboracion.
HUP0300205A2 (en) Aurora 2 kinase inhibitor quinazoline derivatives, preparation and use thereof
GT200200073A (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2-ona
UY32180A (es) Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
GT200200072A (es) Derivados de dihidro-benzo (b) (1,4)-diazepin-2-ona
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
CR9386A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
GR3025926T3 (en) Condensed pyrimidine derivatives and their use as angiotensine II antagonists
AR040349A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
CY1110619T1 (el) Ετεροκυκλικες συμπυκνωμενες ενωσεις χρησιμες ως αντιδιουρητικοι παραγοντες
CY1109729T1 (el) Τερφαινυλ παραγωγα για θεραπεια της νοσου του alzheimer
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
MX2010000658A (es) Derivados de pirimidina 934.
PE20030653A1 (es) COMPUESTOS BICICLICOS[1,2,4]-TRIAZOL COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
CO4650117A1 (es) Derivados de bencilsulfuro y proceso para su produccion .
ES2160106T3 (es) Derivados de la quinazolina.
PE20040757A1 (es) Derivados de benzoxazina
AR065904A1 (es) Heterociclos como antagonistas de orexina
ES2142397T3 (es) Derivado de morfolina.
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos